In combination with azacitidine or decitabine, or reduced-dose cytarabine in newly diagnosed AML aged ≥ seventy five a long time or with co-morbidities that preclude the use of intensive induction chemotherapy Immune checkpoint inhibitors. A vital A part of the immune procedure is its power to preserve itself from attacking https://directivepublications.org/journal-of-leukemia-research/